The Institute for Clinical and Economic Review’s (ICER) Steven Pearson and Sarah Emond in a recent blog post outline the benefits to independent value assessments and how they can help states curb drug prices.
Pearson and Emond write that independent, transparent reports provide “a fair benchmark with which to evaluate drug prices set by manufacturers.”
“While the federal government may remain in deadlock over this for years to come, states have the flexibility to align drug prices fairly with the benefits they provide,” they write. “By continuing to produce independent reports that put evidence at the center of the equation, we hope ICER can support multiple and even coordinated efforts to find solutions.”
To read the full blog post on the California Health Care Foundation’s website, click here.